- Home
- BETR vs PRQR Comparison
BETR vs PRQR Comparison
Compare BETR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- PRQR
- Stock Information
- Founded
- BETR 2014
- PRQR 2012
- Country
- BETR United States
- PRQR Netherlands
- Employees
- BETR N/A
- PRQR N/A
- Industry
- BETR Finance: Consumer Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BETR Finance
- PRQR Health Care
- Exchange
- BETR Nasdaq
- PRQR Nasdaq
- Market Cap
- BETR 203.4M
- PRQR 232.8M
- IPO Year
- BETR N/A
- PRQR 2014
- Fundamental
- Price
- BETR $24.99
- PRQR $2.19
- Analyst Decision
- BETR
- PRQR Strong Buy
- Analyst Count
- BETR 0
- PRQR 8
- Target Price
- BETR N/A
- PRQR $8.88
- AVG Volume (30 Days)
- BETR 72.2K
- PRQR 347.9K
- Earning Date
- BETR 11-12-2025
- PRQR 11-06-2025
- Dividend Yield
- BETR N/A
- PRQR N/A
- EPS Growth
- BETR N/A
- PRQR N/A
- EPS
- BETR N/A
- PRQR N/A
- Revenue
- BETR $130,672,000.00
- PRQR $20,129,184.00
- Revenue This Year
- BETR $55.38
- PRQR N/A
- Revenue Next Year
- BETR $71.18
- PRQR N/A
- P/E Ratio
- BETR N/A
- PRQR N/A
- Revenue Growth
- BETR 69.42
- PRQR 8.65
- 52 Week Low
- BETR $7.71
- PRQR $1.07
- 52 Week High
- BETR $25.94
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- BETR 73.89
- PRQR 47.76
- Support Level
- BETR $23.65
- PRQR $2.21
- Resistance Level
- BETR $25.37
- PRQR $2.50
- Average True Range (ATR)
- BETR 1.49
- PRQR 0.14
- MACD
- BETR 0.19
- PRQR -0.01
- Stochastic Oscillator
- BETR 88.30
- PRQR 32.61
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.